BackAyala Pharmaceuticals Overview

Ayala Pharmaceuticals Other Current Assets

Track Ayala Pharmaceuticals's other current assets ($780K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$780000.00
71.72% YoYΔ $-1.98M vs prior year quarter

Peer average

Loading

Ayala Pharmaceuticals Other Current Assets History

Loading

Ayala Pharmaceuticals vs. peers: Other Current Assets Comparison

Loading

Ayala Pharmaceuticals Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Ayala Pharmaceuticals (AYLA) FAQ

Ayala Pharmaceuticals's other current assets stands at $780K as of December 2022. That compares with $2.8M in the prior-year period — down 71.7% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Ayala Pharmaceuticals reported $780K in other current assets versus $2.8M a year earlier — a 71.7% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $2.8M in the prior-year period — down 71.7% year over year. Sustained growth in other current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Ayala Pharmaceuticals's other current assets evolved across reporting periods, while the comparison chart places AYLA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other current assets is commonly used to spot outliers. Ayala Pharmaceuticals's reading of $780K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.